Systematic review on the safety of concomitant use of hypoglycemia-inducing drugs and non-steroidal anti-inflammatory drugs in patients with musculoskeletal pathology;Revisión sistemática sobre la seguridad del uso concomitante de fármacos hipoglucemiantes y antiinflamatorios no esteroideos en pacientes con enfermedad reumática

Reumatologia Clinica

Volumn 4, Issue 6, 2008, Pages 232-239

  Loza, Estíbaliz ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Hypoglycemia inducing drugs; Non steroidal anti inflammatory drugs; Steroids

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIFLUNISAL; ETORICOXIB; GLIBENCLAMIDE; GLIPIZIDE; GLIQUIDONE; INDOMETACIN; INSULIN; KETOPROFEN; METFORMIN; MIGLITOL; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARECOXIB; PHENYLBUTAZONE; PIOGLITAZONE; REPAGLINIDE; ROFECOXIB; ROSIGLITAZONE; SALICYLIC ACID; SULINDAC; TOLBUTAMIDE; TOLMETIN; UNINDEXED DRUG; VALDECOXIB;

DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; MUSCULOSKELETAL DISEASE; REVIEW; SYSTEMATIC REVIEW;

EID: 58149386570     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(08)75544-X     Document Type: Article

References (36)

1. Lanas A. Advances in the adverse effects of NSAIDs in the gastrointestinal tract. Gastroenterol Hepatol. 2006;29 Suppl 3:16-22.
2. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-96.
3. Price G. Metformin lactic acidosis, acute renal failure and rofecoxib. Br J Anaesth. 2003;91:909-10.
4. Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, et al. Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006;46:1328-36.
5. Zitzmann S, Reimann IR, Schmechel H. Severe hypoglycemia in an elderly patient treated with metformin. Int J Clin Pharmacol Ther. 2002;40:108-10.
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
7. Baggio B, Briani G, Cicerello E, Gambaro G, Giorato C, Iori E, et al. Effects of imidazole-2-hydroxibenzoate on glycosaminoglycan and albumin urinary excretion in type 1 diabetic patients. Nephron. 1988;50:45-9.
8. Christiansen JS, Feldt-Rasmussen B, Parving HH. Short-term inhibition of prostaglandin synthesis has no effect on the elevated glomerular filtration rate of early insulin-dependent diabetes. Diabet Med. 1985;2:17-20.
9. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med. 1987;147:1442-4.
10. Cunha-Vaz JG, Mota CC, Leite EC, Abreu JR, Ruas MA. Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy. Arch Ophthalmol. 1985;103:1307-11.
11. Hattori Y, Hashizume K, Nakajima K, Nishimura Y, Naka M, Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Curr Med Res Opin. 2007;23:1913-7.
12. Hommel E, Mathiesen E, Arnold-Larsen S, Edsberg B, Olsen UB, Parving HH. Effects of indomethacin on kidney function in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia. 1987;30:78-81.
13. Nilsen L, Djoseland O, Rootwelt K, Berg KJ. Effects of short-term treatment with naproxen on kidney function in insulin-dependent diabetic patients with microalbuminuria. Scand J Clin Lab Invest. 1991;51:591-7.
14. Oli JM, Ikeakor IP. The use of piroxicam in diabetics with arthropathies. Curr Ther Res Clin Exp. 1984;36:46-50.
15. Pedrazzi F, Bommartini F, Freddo J, Emanueli A. A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients. Eur J Rheumatol Inflamm. 1981;4:26-31.
16. Shah SJ, Bhandarkar SD, Satoskar RS. Drug interaction between chlorpropamide and non-steroidal anti-inflammatory drugs, ibuprofen and phenylbutazone. Int J Clin Pharmacol Ther Toxicol. 1984;22:470-2.
17. Whiting B, Williams RL, Lorenzi M, Varady JC, Robins DS. Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics. Br J Clin Pharmacol. 1981;11:295-302.
18. Aguilar Munoz A, De la Cruz Cortes JP, Martos Crespo F, Garcia Arnes J, De Pablo Molina J, Sanchez de la Cuesta F. [Effect of dipyridamole (225 mg/day) and acetylsalicylic acid (150 mg/day) on various platelet parameters in non-complicated diabetes mellitus]. Med Clin (Barc). 1986;86:712-5.
19. Anderson DM, Shelley S, Crick N, Buraglio M. A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. Int J Clin Pharmacol Ther. 2002;40:457-64.
20. Bakris GL, Starke U, Heifets M, Polack D, Smith M, Leurgans S. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995;5:1684-8.
21. Chlud K, Kaik B. Clinical studies of the interaction between tolmetin and glibenclamide. Int J Clin Pharmacol Biopharm. 1977;15:409-10.
22. Day RO, Geisslinger G, Paull P, Williams KM. The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers. Int J Clin Pharmacol Ther. 1995;33:308-10.
23. De Cosmo S, Earle K, Morocutti A, Walker J, Ruggenenti P, Remuzzi G, et al. Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion. Diabetologia. 1993;36:622-7.
24. Farker K, Merkel U, Schweer H, Haerting J, Madani SF, Eggers R, et al. Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2 diabetes. Eur J Clin Pharmacol. 2002;58:85-91.
25. Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, et al. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide. Br J Clin Pharmacol. 1990;30:245-52.
26. Haupt E, Hoppe FK, Rechziegler H, Zundorf P. On the question of interaction between nonsteroidal anti-inflammatory drugs and oral antidiabetics: acemetacin - glibenclamide. Z Rheumatol. 1987;46:170-3.
27. Kubacka RT, Antal EJ, Juhl RP, Welshman IR. Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Ann Pharmacother. 1996;30:20-6.
28. Mathiesen ER, Hommel E, Olsen UB, Parving HH. Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy. Diabet Med. 1988;5:145-9.
29. Micossi P, Pontiroli AE, Baron SH, Tamayo RC, Lengel F, Bevilacqua M, et al. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes. 1978;27:1196-204.
30. Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA. Effect of pirprofen on glibenclamide kinetics and response. Br J Clin Pharmacol. 1982;14:123-6.
31. Pereira Arias AM, Romijn JA, Corssmit EP, Ackermans MT, Nijpels G, Endert E, et al. Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus. Metabolism. 2000;49:839-44.
32. Pereira Arias AM, Bisschop PH, Ackermans MT, Endert E, Romijn JA, Sauerwein HP. Indomethacin does not affect endogenous glucose production in type 2 diabetes mellitus. Horm Metab Res. 2001;33:659-63.
33. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care. 1993;16:1103-15.
34. Rudberg S, Satterstrom G, Dahlqvist R, Dahlquist G. Indomethacin but not metoprolol reduces exercise-induced albumin excretion rate in type 1 diabetic patients with microalbuminuria. Diabet Med. 1993;10:460-4.
35. Sharma YR, Vajpayee RB, Bhatnagar R, Mohan M, Azad RV, Kumar M, et al. Topical sulindac therapy in diabetic senile cataracts: cataract-IV. Indian J Ophthalmol. 1989;37:127-33.
36. Shimura M, Nakazawa T, Yasuda K, Nishida K. Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther. 2007;23:284-91.